Eli Lilly Deep Value Research: A Great Company at Too High a Price

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?7/10

  A

  The ceiling is extremely high, and Lilly is expanding a huge existing pie that has long been underserved, rather than creating a new market from scratch. This is the strongest foundation of Lilly's current valuation story, but it is important to separate 2 questions: how large the demand pool is, and how much net value the company can capture.

  The demand side hardly needs debate. The patient-pool data cited in the report can be checked against primary sources: CDC data show that the U.S. adult obesity rate was about 40.3% in 2021-2023; the WHO 2025 obesity and overweight fact sheet states that in 2022 about 16% of adults globally, more than 890 million people, were living with obesity; and the International Diabetes Federation IDF Diabetes Atlas estimates that about 589 million adults aged 20-79 worldwide had diabetes in 2024. This is not discretionary consumption. It is a global patient pool with chronic-disease characteristics and long-term rigidity, exactly the kind of long-runway, deep-snow market favored by the Baillie LTGG lens.

  But it is necessary to distinguish honestly between creation and expansion. The GLP-1 / GIP metabolic drug category was not invented from nothing by Lilly: drug treatment for diabetes and weight loss already existed. Tirzepatide, marketed as Mounjaro/Zepbound, and Novo's semaglutide pushed efficacy, adherence, and indications to a new level, converting an obesity population that had always existed but had long been undertreated into real paid demand. A more accurate description is this: Lilly is using a generational clinical leap inside an enormous existing necessity market to greatly expand the reachable, payable penetration layer. It is expanding the pie, not creating the pie.

  The real constraint on the ceiling is not how many patients exist, but the product of net price x penetration x sustainable margin. The report already makes this point, and the latest results confirm it: Lilly's Q1 2026 results show quarterly revenue of about $19.8 billion, up 56% year over year, but the growth structure was volume +65% and realized net price −13%. Volume is surging, while payers are pressing price downward. In other words, the pie is getting bigger, but the sweetness of each bite, the net price, is being thinned by rebates, PBM negotiations, and international reference pricing.

  My judgment: the market ceiling is high enough to support a decade-level growth narrative, and this is the strongest part of the bullish case. But a high ceiling does not mean buying today at about $1136 and a market cap above $1 trillion is safe. The huge demand pool has long been consensus and has been repeatedly priced in. The true uncertainty is not TAM, but the net price and sustainable margin at which Lilly can convert this large pie into distributable owner cash flow.

  Jun 10, 2026
• QCan its revenue at least double over the next 5 years? Will growth be driven mainly by volume, price, or new businesses?7/10

  A

  A revenue doubling over the next 5 years is highly likely, and it will be driven mainly by volume, with new businesses, oral GLP-1 and triple agonists, adding support, rather than by price increases. That is exactly where the concern lies. The doubling hurdle is not especially high for today's Lilly. The company's own guidance has already taken it more than halfway down that road.

  Start with the base and the slope. Lilly reported FY2025 revenue of about $65.179 billion, up +45% year over year, and Q1 2026 revenue of about $19.8 billion, up +56%, while raising full-year guidance to a range of $82-85 billion, with the midpoint implying annual growth of about 28%. Extrapolate that slope forward: moving from about $65.2 billion in 2025 to a doubling requires about $130 billion. At the current growth rate, this does not require a miracle. Roughly speaking, Lilly only needs to maintain mid-to-high-teens growth over the next few years. Doubling in 5 years is a conservative rather than optimistic scenario.

  The growth-source breakdown is very clear: almost all volume, almost not price. The same Q1 report disclosed that 56% revenue growth was driven by volume +65%, partly offset by realized net price −13%. By region, U.S. revenue was +43%, with volume +49% and price −7%; revenue outside the U.S. was +81%, with volume +95% and price −25%. This shows that the ramp is mainly coming from higher penetration and international rollout, while price is being pushed steadily down, especially in international markets. Under the Baillie framework, volume-driven high growth is healthy in itself, because it shows real demand rather than numbers propped up by price hikes. But systematic price decline means margin sustainability and net price have to be questioned even as revenue doubles.

  The new-business growth curve is real and has already landed, not a PowerPoint story. The oral GLP-1 Foundayo, orforglipron, was approved by the FDA on April 1, 2026 for obesity. It is the first weight-loss GLP-1 pill that can be taken at any time of day without food or water restrictions. The triple agonist retatrutide's Phase 3 TRIUMPH-1 data showed average weight loss of 28.3% at the highest dose over 80 weeks. Oral dosing can break through the capacity and cold-chain bottlenecks of injectables and open a much broader population with better adherence. It is one of the most realistic volume accelerators for the next 5 years.

  My judgment: Lilly is highly likely to get the 5-year doubling question right, and bulls are unlikely to lose on that point. But 2 risks matter. First, the doubling comes from volume, not price, while payers are steadily thinning price, so revenue doubling may not translate proportionately into profit doubling. Second, the current market cap of about $1 trillion already prices continued high-speed volume ramp as the base case, with trailing P/E of about 39-40x. So the ability to double is not a reason that buying at today's price is attractive. It is the downside risk if Lilly fails to double that matters.

  Jun 10, 2026
• QAfter 5 years, what will take over as the next growth engine? Does that second curve exist today?5/10

  A

  The second curve already exists today, and there is more than 1. This is the key difference between Lilly and a company built around a single trick, and it is the main basis for saying the moat is widening. But honesty matters: most of these second curves still sit inside the same broad metabolic arena. They are deeper extensions of the platform, more like the next-stage rocket of the main curve than a truly independent growth pole outside the weight-loss story.

  The most certain second curve is oral GLP-1, Foundayo / orforglipron. It was approved by the FDA on April 1, 2026 for obesity, and the ATTAIN-1 Phase 3 trial showed weight loss of up to about 12.4% over 72 weeks. Its strategic significance is not that it is more powerful than injectables, because the weight-loss magnitude is actually below tirzepatide. Its significance is a dosage-form revolution: an oral small molecule escapes the cold-chain and sterile fill-finish capacity bottlenecks of injectables, and can reach a huge population that resists needles or has limited ability to pay in emerging markets, at lower unit cost and through broader channels. It is a tool for pushing the same obesity market one order of magnitude deeper.

  The second is the triple agonist retatrutide. Its Phase 3 TRIUMPH-1 data showed average weight loss of 28.3% at the highest 12mg dose over 80 weeks, and patients with baseline BMI≥35 reached average weight loss of 30.3% in the 104-week extension, approaching bariatric-surgery-level efficacy. It targets patients with severe obesity where the efficacy ceiling is higher, and is the next-generation flagship after tirzepatide.

  But the bullish narrative needs cooling: these 2 curves are still highly concentrated in the single basket of weight loss / metabolism. The report itself acknowledges that the cardiometabolic business already accounted for about 80% of revenue in Q1 2026, according to the quarterly results. The second curve in the truer sense, one that breaks out of metabolism, such as Kisunla, donanemab, for Alzheimer's disease, Verzenio in oncology, or the immunology pipeline, is still relatively small and contributes far less at the margin to overall growth than the GLP-1 platform. This means Lilly's second curve should be understood more as generational relay inside the metabolic platform, tirzepatide to oral to triple agonist, rather than risk diversification through business diversification. If the entire incretin category faces a systemic shock, such as a major safety signal, collective payer price pressure, or a competitor's technological breakthrough, multiple curves will come under pressure at the same time and cannot hedge one another.

  My judgment: measured by Baillie's question of whether the second curve exists today, Lilly is one of the few companies that can clearly answer yes, and that it has already landed and received approval. This is one hard support for its growth premium. But measured by diversification, these curves share the same origin, arena, and payer environment. The moat is getting deeper in metabolism, not broader across unrelated domains. For a buyer today at about $1136 and a market cap above $1 trillion, much of the second curve is already in the price. It can prevent a growth cliff, but it does not create a new reason that today's price still offers a margin of safety.

  Jun 10, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next 3 to 5 years?6/10

  A

  The core moat is a 4-part combination of patents, clinical data, regulatory access, and scaled manufacturing. Over the next 3 to 5 years, the broad direction is stable to slightly wider, but a narrowing line is also embedded inside that widening: payer price pressure. This is not a single trench. It is a layered composite barrier, which is the typical profile of a high-quality innovative-drug platform.

  The first and most fundamental layer is patent and regulatory barriers. Innovative drugs require sustained heavy investment and clinical success. Lilly's FY2025 R&D spending was about $13.3 billion. Even if competitors want to copy it, they must repeat a multi-year journey from molecule to Phase 3 trials to FDA approval. Lilly is not living off 1 or 2 lucky drug successes: oral Foundayo was approved in April 2026, and the triple agonist retatrutide produced Phase 3 data showing 28.3% weight loss over 80 weeks. The product ladder keeps extending, and that is the core evidence of widening.

  The second layer is scaled manufacturing capability, a moat that capital has rapidly deepened in recent years. The report notes that Lilly's FY2025 purchases of property and equipment were about $7.841 billion, above about $5.058 billion in 2024, and that the company clearly expects capital expenditures to remain significantly elevated in the near term. Sterile fill-finish capacity and supply chains for GLP-1 injectables are extremely hard to replicate quickly. The 10-K directly says that adding or transferring capacity takes a very long time, substantial capital, and regulatory approvals. That means even if a rival holds an equally effective molecule, it may not be able to scale and deliver commercially at speed. This is the physical basis of Lilly's current advantage of having product to sell while rivals are short.

  The third layer is proven market leadership. The strongest rival is Novo Nordisk. The Novo data cited by the report show that Novo still has 59.6% global volume share in branded obesity GLP-1s. But the key inflection is that Lilly has overtaken Novo in the U.S. GLP-1 market, with about 60% U.S. share versus about 40% for Novo, while Novo has guided to a 4%-12% sales decline for 2026. This share shift is the most direct market evidence that Lilly's moat is widening.

  But the narrowing line must be stated plainly: pricing power is limited and is being eroded by payers. This is not conjecture. It is hard evidence from the financials: in Q1 2026, revenue was +56%, but realized net price was −13%, and international net price was −25%. The report is accurate here: Lilly has clinical-value-driven bargaining power, not monopoly power to raise prices at will. Once obesity drugs move from shortage to sufficient supply, the market narrative will shift from who has product to whose profit structure is better. At that point, net-price pressure will hit the earnings conversion of the moat more directly. High gross margin is still holding, with FY2025 gross margin of about 83% and Q1 2026 about 82%, according to the results. That is the key vital sign showing the moat has not yet been filled in.

  My judgment: overall, a net widening of the moat over the next 3 to 5 years is the more likely direction, driven mainly by manufacturing scale and generational product relay. This supports Lilly's classification as a high-quality platform. But moat widening is a business-quality question, and whether it is worth buying at the current price of $1136 and a market cap above $1 trillion is a separate question. Even a very wide moat does not change the fact that the market has already paid a rich premium for that moat.

  Jun 10, 2026
• QIf its core business is disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?5/10

  A

  Lilly has a fairly strong reinvention DNA, but that DNA looks more like the innate survival instinct of an R&D-driven pharmaceutical company than a trait forged by surviving a near-death crisis. What Baillie is really asking is this: if the core business is disrupted, does this company have the ability to change its life and keep going? For a nearly 200-year-old pharmaceutical company, the answer is positive, but it needs to be viewed in 2 layers.

  The first layer is institutionalized R&D regeneration, which is the structural and most credible reinvention gene. The essence of the innovative-drug industry is the perpetual cycle of patent cliff to pipeline succession: every generation of blockbuster drugs eventually loses patent protection and is eaten into by generics. If a company cannot keep producing the next generation of molecules, it declines. Lilly has maintained this cycle well through about $13.3 billion of FY2025 R&D spending and continuous external BD. The evidence is that while tirzepatide is still in its prime, Lilly has already pushed oral Foundayo to approval and advanced the triple agonist retatrutide to Phase 3 success. This is an active posture of disrupting its own best product with its next generation before someone else does, and it is exactly what anti-disruption capability looks like.

  Historically, Lilly also has a record of reinventing from a trough: in the previous decade, it went through growth stagnation after patent expirations on blockbusters such as Alimta and Cymbalta, then reemerged through later R&D pipelines, including the diabetes line tirzepatide. This shows that it has not merely avoided the shock of core-product failure; it has endured it and come through. That experience of crossing patent cycles is itself evidence of reinvention DNA.

  The second layer, and the one that needs more caution, is this: how does it handle mistakes and bad news? The evidence here is more neutral. On the positive side, the report describes a relatively sound governance structure: executives are prohibited from hedging or pledging shares, the company has a clawback policy, and the CEO and executives face mandatory shareholding requirements. According to the report, CEO David Ricks' actual holdings reached 412 times the salary requirement. These mechanisms structurally reduce management's incentive to hide bad news or chase the short-term share price. The report also acknowledges that the company has proactively disclosed product-liability litigation related to incretin drugs, and in its financial results has honestly recognized realized net-price pressure on Mounjaro/Zepbound, with Q1 2026 net price −13%. It did not dress up this headwind, which is evidence of facing bad news honestly.

  But one reservation is necessary: Lilly has not yet gone through a true crisis test in the GLP-1 era. The past few years have been unusually smooth. The organization's resilience is still more a confidence derived from historical inference and institutional design than something repeatedly tested in the recent past. The real stress tests, such as a major safety signal in a core product or collective payer price pressure that structurally steps down gross margin, have not yet arrived.

  My judgment: Lilly's reinvention DNA is credible but not recently battle-tested. It is stronger than most growth stocks dependent on a single product, but weaker than companies that recently crossed a life-or-death crisis and then proved their resilience after being forced to reinvent. Under the Baillie framework, this is a positive but not a capped-out item. It supports confidence in long-term ownership, but it does not change the valuation reality that today's roughly $1136 price and market cap above $1 trillion are pricing a favorable scenario with almost no buffer for bad news.

  Jun 10, 2026
• QDoes management, especially the founder, have a long-term view and deep alignment with the company? Is it willing to sacrifice current profit for 5 to 10 years from now?5/10

  A

  Management's long-term orientation and economic alignment are both relatively strong, and governance is above average among large pharmaceutical companies. But Lilly is a professional-manager company with no founder, and the current incentive plan still puts substantial weight on short- and medium-term financial metrics. The evidence that it is willing to sacrifice current profit for 5 to 10 years from now is behavioral, through continued heavy reinvestment in R&D and capacity, rather than built into the compensation design.

  Start with alignment, the hardest evidence. According to the company proxy cited by the report, CEO David Ricks' shareholding requirement is 12 times salary, while his actual holdings are as high as 412 times. The CFO requirement is 8 times, and other executives' requirement is 6 times. All disclosed core executives, the NEOs, meet their shareholding requirements. The company prohibits executives from hedging or pledging shares and has a clawback policy. This combination means executives' personal wealth is deeply tied to the share price and cannot be secretly hedged through financial derivatives. Among large companies where long-termism is often verbal while actual holdings are light, Lilly is clearly on the better end. One distinction needs to be made: this is strong alignment between professional managers and shareholders, not the natural alignment between a founder and the company. Lilly does not have a founder at the helm who has staked a personal fortune and life's work on the company. That is a structural gap versus the founder-led growth companies Baillie loves most.

  On the willingness to sacrifice current profit for the long term, the behavioral evidence is strong. The report shows that the company has directed huge amounts of cash to 2 items that depress near-term free cash flow: first, about $7.841 billion of FY2025 purchases of property and equipment, with the company clearly saying near-term capex will remain significantly elevated; and second, high-intensity R&D and external BD, with FY2025 R&D of about $13.3 billion and acquired IPR&D running at a several-billion-dollar scale in recent years. These outlays genuinely consume cash today and depress reported free cash flow, but the purpose is to prepare capacity and pipeline for 5 to 10 years from now. That is actual sacrifice for the long term, not a slogan.

  But the incentive design itself deserves a discount. According to the report, the 3 metrics for the 2025 annual cash bonus were product revenue, EPS, and pipeline progress, each weighted 1 third, and the final bonus paid out at 218% of target. The risk in this structure is that product revenue and EPS are short- to medium-term financial metrics and can push management toward near-term results. The good side is that pipeline progress at least carries equal weight, and mandatory shareholding plus the hedging ban partly soften short-termism. So the incentive structure is good enough but imperfect. It does not hard-code long-termism into the compensation formula, and relies more on shareholding alignment and corporate culture as the backstop.

  There is also a capital-allocation point to watch: the report notes that the company continued large-scale buybacks during a high-valuation phase. According to the report, FY2025 buybacks were about $4.1 billion, and of the $15 billion repurchase authorization approved in December 2024, about $10.9 billion remained at the end of 2025. For long-term shareholders, buybacks are not inherently virtuous. They are high-quality capital allocation only when the shares are undervalued. Continuing buybacks at today's elevated price of about $1136 and a market cap above $1 trillion may not be optimal in return terms. This shows that management's long-term view is expressed mainly through investing in R&D and capacity, while the timing of buybacks is somewhat mechanical and not sufficiently contrarian.

  My judgment: Lilly scores excellent but not exceptional on management. Alignment is strong, and the behavioral evidence of long-term investment is solid, but it lacks a founder, incentives lean short- to medium-term, and high-price buybacks are not restrained enough. This supports confidence in following the company for the long term, but like every previous dimension, strong governance is not a reason that buying at today's price is safe.

  Jun 10, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not dependent on harming society or regulation?6/10

  A

  If Lilly disappeared tomorrow, millions of patients currently using its medicines would miss it immediately and intensely. Its indispensability is extremely high. But on social and regulatory sustainability, its growth model is precisely one of the weakest links in the entire investment case. This Baillie question needs a 2-part answer: indispensability, which is strong, and sustainability, which is questionable, must be separated.

  Start with indispensability, where there is no real dispute. GLP-1 / GIP drugs are not nice-to-have discretionary consumption for patients with obesity and diabetes. They are treatments that directly change the disease trajectory. Retatrutide Phase 3 data show weight loss of up to 28.3% at the highest dose and 30.3% in the severe-obesity extension population, approaching the effect of bariatric surgery. For a patient using Mounjaro to control blood sugar or Zepbound to lose weight, stopping treatment means weight regain and worsening metabolic markers. This rigidity, where withdrawal leads to deterioration, combined with Lilly's about 60% share of the U.S. GLP-1 market and its lead in manufacturing capacity, creates a very strong sense of irreplaceability among patients and physicians. The only substitute, Novo Nordisk, also cannot quickly fill the supply gap that Lilly would leave. From this angle, Lilly passes Baillie's would-customers-miss-you test with a high score.

  But the sustainability side deserves serious questions, and the questions fall squarely on society and regulation. The issue is not whether the product works. It is whether the way this business earns money will trigger systemic pushback from payers and regulators because it is too expensive, too profitable, and too visible. The evidence is direct:

  First, net price is already being pushed down continuously by payers and policy. Lilly's Q1 2026 results show revenue +56%, but realized net price −13% and net price outside the U.S. −25%. The report also clearly notes that insurance coverage for obesity drugs, voluntary pricing agreements, and international reference pricing, including policy frameworks such as the IRA, may continue to compress net price. This means Lilly's high-profit portion rests on a temporary window in which payers have not yet pushed pricing all the way down.

  Second, whether obesity drugs should be paid for at large scale by public insurance is itself an unresolved social question. The patient pool is enormous. The CDC puts the U.S. adult obesity rate at about 40%. If all of this were covered by Medicare/Medicaid, the fiscal pressure would be huge, and more aggressive price negotiation would inevitably follow. Lilly is also responding proactively: Foundayo introduced out-of-pocket programs with as little as $25 per month for commercial insurance and $50 per month for Medicare Part D, and expanded the LillyDirect self-pay channel. These actions improve access, which is socially positive, but they also show that the model of quietly earning large profits at high net prices is not politically or publicly sustainable. The company is being forced to share value proactively.

  Third, product-liability litigation is another reef. The report discloses that the company has made disclosures about litigation related to incretin drugs. It is not a fatal threat in the near term, but it is a social cost that a highly profitable and highly visible business can hardly avoid.

  My judgment: Lilly's indispensability is textbook-grade, with deterioration after discontinuation, leading share, and scarce supply. This half of the answer is strong and is a solid reason for long-term ownership. But on social and regulatory sustainability, its growth model clearly depends on a net-price window that is still narrowing. Growth is not based on harming society, because the products genuinely help patients, but it is highly exposed to the countermeasure risk that society decides the company is earning too much and uses regulation to push prices down. For a buyer today at about $1136 and a market cap above $1 trillion, this sustainability risk is not fully priced and is a more hidden long-term variable than competition.

  Jun 10, 2026
• QWhat are the unit economics of this business, including gross margin and incremental returns? Do they improve or deteriorate with scale? Where does the money earned go?8/10

  A

  The unit economics are exceptionally strong: gross margin is about 82-83%, and operating leverage continues to expand as scale grows. This is hard evidence of Lilly's business quality. But a large share of the money earned is being consumed by massive capacity expansion and external acquisitions, creating a clear gap between accounting profit and truly distributable cash. This question requires an honest separation between how beautiful the income statement looks and how light the cash flow really is.

  Start with gross margin and incremental returns, which are genuinely top-tier. Lilly's FY2025 gross margin was about 83.0%, and Q1 2026 gross margin was about 82%. More important, as scale expands, unit economics are improving rather than deteriorating. The report shows operating margin jumped from about 18.9% in 2023 to about 40.4% in FY2025, net margin was about 31.7%, and company IR disclosed FY2025 ROE as high as 101.36%. This is the classic combination of high-gross-margin innovative drugs and operating leverage. When revenue doubles, fixed R&D and selling expenses are spread across a larger base, and profit grows faster, with FY2025 net income of about $20.640 billion, nearly doubling year over year. The flywheel Baillie likes, where larger scale brings better unit economics, is visible on Lilly's income statement.

  But the sub-question of where the money earned goes exposes the other side of the income statement. The report makes a very important and honest breakdown: if only property and equipment capex is deducted, FY2025 free cash flow was about $8.969 billion; but under the company's IR definition, which also deducts purchases of intangibles, or external BD, FY2025 free cash flow was only about $5.961 billion. The 2 definitions differ by about $3 billion. The essence of the difference is not accounting manipulation, but the fact that Lilly is doing 2 cash-consuming things at the same time:

  First, massive manufacturing expansion. FY2025 purchases of property and equipment were about $7.841 billion, above about $5.058 billion in 2024, to build capacity for GLP-1 injectables and oral products. Second, high-intensity external BD: acquired IPR&D has continued to run at a several-billion-dollar scale in recent years, and by Q1 2026 the company had also disclosed pending acquisitions with potential closing amounts of up to about $12 billion. Third, working capital is also absorbing a lot of cash. The report notes that 2025 accounts receivable rose to about $20.155 billion and inventory to about $13.744 billion. Explosive volume growth comes with channel replenishment and global rollout; growth is not cost-free.

  This leads to the report's most restrained and important judgment: Lilly's profit is broadly real profit, but true distributable cash flow is materially below the apparent growth rate of profit, at least over the past 2 to 3 years. Based on this, the report puts conservative Owner Earnings in a range of $18-22 billion, with a midpoint of about $20 billion, clearly below the reported net income of about $20.6 billion.

  How should this cash consumption be characterized? Both sides matter. A large part of the expansion spending is growth capex, laying the ground for higher future output, and should not be mechanically treated as maintenance cost. This money is being spent for good reason, to deepen the moat. But the quality of external BD needs time to prove itself. The report's warning is accurate: if these investments cannot convert into sustainable ROIC, they will turn from strategic reinvestment into an expensive growth illusion.

  My judgment: Lilly scores highly on unit economics. Gross margin, incremental returns, and scale leverage are textbook-grade, and this is central to its high-quality platform status. But the where-the-money-goes part requires caution: at this stage, large amounts of cash are tied up in capacity expansion, BD, and working capital, so owner cash flow is not as light as EPS suggests. Against today's price of about $1136 and market cap above $1 trillion, if measured against about $20 billion of midpoint Owner Earnings, the earnings multiple has risen to about 50x, far above the about 34-35x calculated by the report using the roughly $69.4 billion market cap at the time of writing. Even outstanding unit economics struggle to support a margin of safety at this price.

  Jun 10, 2026
• QWhat conditions must all be true for it to rise 5-fold over 10 years? Are those conditions realistic? What expectations are implied by today's share price?3/10

  A

  Starting from today's roughly $1136 price and market cap above $1 trillion, a 5-fold increase over 10 years is an extremely demanding problem that requires multiple difficult conditions to hold at the same time. It is harder than when the report was written, at about $732, because the share price has already moved up first. Baillie's 10-year 5-bagger firepower should be concentrated in years 3-10, but only if the entry price has not already pulled too much of the future forward. Lilly's current price has already priced in a substantial part of that future.

  Translate the 5-fold target into a concrete math hurdle first. A 5-fold return over 10 years is about a 17.5% annualized share-price return. Starting from a market cap of about $1 trillion, 5-fold means the market cap would need to move toward about $5 trillion, making Lilly one of the largest companies by market value in human history. To support that valuation, assuming the valuation multiple does not expand, and may even contract modestly because giants rarely sustain high multiples, owner earnings would also need to rise roughly 5-fold. The report's current midpoint estimate for Owner Earnings is about $20 billion. A 5-fold increase means roughly $100 billion of distributable earnings 10 years from now.

  For this to happen, at least the following conditions must be true simultaneously:

  First, global penetration of the GLP-1 / metabolic platform must keep rising rapidly and not be offset by a collapse in net price. Today's growth is almost all volume, with Q1 2026 volume +65% and net price −13%. The 5-fold story requires volume growth to keep overwhelming price decline over the next 10 years, which means net price must not fall off a cliff after obesity drugs move from shortage to abundant supply. This is the biggest uncertainty.

  Second, next-generation assets, oral Foundayo and the triple agonist retatrutide, must scale commercially while preserving high gross margin. Foundayo has been approved, and retatrutide succeeded in Phase 3, so the direction has been validated. But large-scale commercial adoption without meaningful margin dilution remains to be proven.

  Third, massive capacity expansion must convert smoothly into high ROIC rather than low-return assets. The current several-billion-dollar annual capex and up to about $12 billion of pending BD must turn into real cash returns over 10 years. The report warns that if these investments cannot convert into sustainable ROIC, they become an expensive growth illusion.

  Fourth, the competitive landscape must not deteriorate. Novo Nordisk still holds about 59.6% global volume share in branded obesity GLP-1s, and next-generation players are chasing. The 5-fold story assumes Lilly continues to widen its lead in a duopoly or even a multi-strong-player market.

  Fifth, there must be no major safety, regulatory, or patent event. Any problem in a core product could puncture the narrative.

  Are these 5 conditions realistic? Looked at one by one, none is fantasy. But requiring all of them to hold at the same time over 10 years, without any major failure, reduces the probability sharply. This is exactly Baillie's discipline: dare to imagine the blue-sky case, but mark the probability honestly.

  What expectations are implied by today's share price? This is the point that must be made clear. A price of about $1136, trailing P/E of about 39-40x, and forward P/E of about 29-30x essentially price most of the above favorable conditions as the base case. The sharper comparison is this: the report's 3 intrinsic-value scenarios, based on a market cap of about $69.4 billion, were conservative $330-420, reasonable $560-680, and optimistic $820-980. The current share price of about $1136 is already above the upper end of the report's own optimistic range, $980. In other words, the market's current price is higher than the report's most optimistic intrinsic value. It is no longer paying in advance for success; it is paying in advance for excess success.

  My judgment: a 10-year 5-fold return is not impossible at the business level, which is why Lilly is different from an ordinary large-cap stock. But starting from today's price, which has already pulled forward the optimistic scenario, the margin of safety required for a 5-fold outcome has been extracted. Buying here means betting not only that Lilly succeeds, but that it succeeds better than the most optimistic expectations. Under the Baillie framework, this is the classic good company, bad price case: worth keeping on the watchlist for long-term tracking, but today's price does not leave room for mistakes in this 10-year 5-bagger wager.

  Jun 10, 2026
• QWhy has the market not realized all this yet? Is it because it cannot understand, does not respect it, or cannot look far enough? What will be the narrative inflection point?3/10

  A

  Frankly, the market has not only realized Lilly's excellence; it has fully, and perhaps excessively, priced that excellence. This is not a mispriced company that the market cannot understand, does not respect, or cannot look far enough to appreciate. On the contrary, it is one of the most crowded-consensus and most thoroughly researched super-growth stocks. The essence of Baillie's question is to find the good that the market has not yet recognized. For Lilly, the honest answer is that the perception gap is very thin. The price itself already reflects almost every bullish argument.

  Start with the price facts. From about $732 when the report was written to about $1136 now and a market cap above $1 trillion, as of June 2026, the share price has risen by about 55% over this period. Trailing P/E is about 39-40x, and forward P/E is about 29-30x. That valuation level is itself evidence that the market understands, respects, and looks far ahead. Lilly is already among the world's largest companies by market cap, with dense institutional coverage and generally high sell-side target prices. Putting Lilly into Baillie's why-has-the-market-not-realized-it frame, the most honest answer is: the market realized it long ago; the question is not perception gap, but whether valuation has already overdrawn the future.

  If one must look for corners where the market may still disagree, there are only 2 somewhat technical gaps, and neither is traditional undervaluation:

  First, the cash-flow definition gap. The report notes a clear gap between Lilly's reported EPS and truly distributable cash flow: under a property-and-equipment-only definition, FY2025 free cash flow was about $8.969 billion, while under the IR definition including intangible purchases it was only about $5.961 billion, according to the 10-K, far below reported net income of about $20.6 billion. Investors looking only at EPS may overestimate Lilly's cash lightness. But this is a reason to be more cautious, not more bullish. It points to today's price being more expensive than the headline P/E suggests, not to the market having missed good news.

  Second, the long-term meaning of sustained net-price decline may be underestimated. The market is currently more focused on impressive volume growth, with Q1 volume +65%. It may not have fully priced the profit-structure repricing implied by net price −13% and international −25% once obesity drugs move from shortage to sufficient supply. This is also a bearish rather than bullish perception gap.

  What will be the narrative inflection point? This is the truly important question for a crowded-consensus, high-valuation leader like Lilly. The inflection is more likely to be downward than upward, because most of the upside story is already priced in. The most likely candidates are:

  Downside inflections, which deserve more caution: several consecutive quarters of trading price for volume, with a structural step-down in gross margin; a major safety or regulatory signal in a core product such as Mounjaro/Zepbound; large-scale U.S. insurance coverage for obesity drugs arriving at the cost of extreme price pressure; Novo or a next-generation competitor producing data that overtakes Lilly's efficacy and breaks the clinical-leadership narrative; or next-generation pipeline assets, oral and triple agonist, scaling below expectations. Any one of these could move the market from pricing perfect execution to pricing normal excellence. The report estimates that such valuation compression combined with slower growth could produce a 30%-45% drawdown.

  Upside inflections, which are harder because many are already priced: after expansion is completed, operating cash flow grows meaningfully faster than revenue and Owner Earnings steps up clearly, proving the cash-flow gap is closing. This is one of the few positive signals that may not be fully priced and could drive further valuation re-rating.

  My judgment: Lilly is not a perception-gap opportunity that the market has missed. It is a high-quality leader that the market understands very well and has priced generously. Under the Baillie framework, its appeal lies in business quality rather than pricing dislocation. At today's price, above the upper end of the report's optimistic range, the narrative inflection is more likely to become a downside risk than an upside catalyst. The real opportunity window will appear only after a valuation pullback or cash-flow delivery pulls the price back into a more comfortable range. This is consistent with the report's conclusion: a good company, but with no obvious margin of safety at the current price, and better placed on a watchlist for patient waiting.

  Jun 10, 2026